Research summary ·
Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Written based on 1 research study on PubMed, searched on 8 Nov 2026.
What was studied
This review compared stent types in coronary artery disease. One is the bioresorbable vascular scaffold (BVS). The other is the contemporary drug-eluting stent (DES). The team pooled randomized and observational studies. The main outcome was a combined clinical endpoint at 1 year. Other outcomes were death, heart attack, repeat procedures, clots and scans of the artery. They also looked at 2, 3 and 5 years. 51 studies were included.
What they found
At 1 year, BVS carried a higher risk of the combined endpoint than DES. The risk ratio was 1.11. This was mainly driven by heart attack, repeat procedures and clots. Death from any cause did not differ significantly. Death from heart causes did not either. Later on, BVS stayed linked to more ischemic events and repeat procedures. Scans showed more late lumen loss with BVS.
What it means for patients
The authors say BVS appears to carry a higher ischemic risk than DES. They say it shows no long-term mortality benefit. They say contemporary DES remains the preferred strategy.
Why it is not certain yet
The trial sequential analysis was inconclusive for the main endpoint. The studies were randomized and observational. The confidence range for the 1-year result reached 1.00. A review can only be as good as the studies in it.
Source
Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
PubMed · PMID 42985635We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Coronary artery disease publications